Cargando…

Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients

Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Rastrelli, Marco, Ferrazzi, Beatrice, Cavallin, Francesco, Chiarion Sileni, Vanna, Pigozzo, Jacopo, Fabozzi, Alessio, Tropea, Saveria, Vecchiato, Antonella, Costa, Alessandra, Parisi, Alessandro, Rossi, Carlo Riccardo, Del Fiore, Paolo, Alaibac, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210570/
https://www.ncbi.nlm.nih.gov/pubmed/30249978
http://dx.doi.org/10.3390/cancers10100350
_version_ 1783367146016866304
author Rastrelli, Marco
Ferrazzi, Beatrice
Cavallin, Francesco
Chiarion Sileni, Vanna
Pigozzo, Jacopo
Fabozzi, Alessio
Tropea, Saveria
Vecchiato, Antonella
Costa, Alessandra
Parisi, Alessandro
Rossi, Carlo Riccardo
Del Fiore, Paolo
Alaibac, Mauro
author_facet Rastrelli, Marco
Ferrazzi, Beatrice
Cavallin, Francesco
Chiarion Sileni, Vanna
Pigozzo, Jacopo
Fabozzi, Alessio
Tropea, Saveria
Vecchiato, Antonella
Costa, Alessandra
Parisi, Alessandro
Rossi, Carlo Riccardo
Del Fiore, Paolo
Alaibac, Mauro
author_sort Rastrelli, Marco
collection PubMed
description Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.
format Online
Article
Text
id pubmed-6210570
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62105702018-11-02 Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients Rastrelli, Marco Ferrazzi, Beatrice Cavallin, Francesco Chiarion Sileni, Vanna Pigozzo, Jacopo Fabozzi, Alessio Tropea, Saveria Vecchiato, Antonella Costa, Alessandra Parisi, Alessandro Rossi, Carlo Riccardo Del Fiore, Paolo Alaibac, Mauro Cancers (Basel) Article Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival. MDPI 2018-09-24 /pmc/articles/PMC6210570/ /pubmed/30249978 http://dx.doi.org/10.3390/cancers10100350 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rastrelli, Marco
Ferrazzi, Beatrice
Cavallin, Francesco
Chiarion Sileni, Vanna
Pigozzo, Jacopo
Fabozzi, Alessio
Tropea, Saveria
Vecchiato, Antonella
Costa, Alessandra
Parisi, Alessandro
Rossi, Carlo Riccardo
Del Fiore, Paolo
Alaibac, Mauro
Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
title Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
title_full Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
title_fullStr Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
title_full_unstemmed Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
title_short Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
title_sort prognostic factors in merkel cell carcinoma: a retrospective single-center study in 90 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210570/
https://www.ncbi.nlm.nih.gov/pubmed/30249978
http://dx.doi.org/10.3390/cancers10100350
work_keys_str_mv AT rastrellimarco prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT ferrazzibeatrice prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT cavallinfrancesco prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT chiarionsilenivanna prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT pigozzojacopo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT fabozzialessio prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT tropeasaveria prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT vecchiatoantonella prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT costaalessandra prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT parisialessandro prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT rossicarloriccardo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT delfiorepaolo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients
AT alaibacmauro prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients